Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Pancreatic Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 5/27/2013 |
| Start Date: | October 2007 |
| End Date: | October 2010 |
| Contact: | Stephen Leong, MD |
| Email: | stephen.leong@ucdenver.edu |
| Phone: | 303-724-3837 |
A Phase I Study of Gemcitabine, Capecitabine and ZD6474 (ZACTIMA) in Patients With Advanced Solid Tumors With an Expanded Cohort of Patients With Biliary or Pancreatic Malignancies.
Zactima will be used in this study to determine the highest dose that can be given safely as
well as the side effects of Zactima when in combination with two FDA approved drugs;
gemcitabine and capecitabine. This combination will be given to patients with advanced solid
tumors. Once the highest dose of the combination has been determined, additional patients
with biliary cancers (cholangiocarcinomas and gallbladder cancer) and locally advanced or
metastatic pancreatic cancer will be treated at the highest determined dose for further
studies.
Inclusion Criteria:
- Age 18 years or older
- ECOG performance status of 0-1 (measure of your ability to perform everyday tasks)
- Life expectancy of at least three months
Blood samples and other testing may apply for further testing of eligibility.
Exclusion Criteria:
- Uncontrolled illness (for example, current infections or heart conditions)
- Abnormal laboratory tests (such as blood or urine testing)
- Pregnant or breastfeeding women
Further exclusion criteria may apply.
We found this trial at
1
site
University of Colorado Denver The University of Colorado Denver | Anschutz Medical Campus provides a...
Click here to add this to my saved trials
